近日，嘉和生物与亿腾医药联合宣布了一项具有深远影响的合并协议，标志着亿腾在上市的道路上迈出了重要一步。 亿腾医药经过多年的转型升级，已逐步发展成为一家具备研发、生产、供应链和销售综合能力的医药企业。而嘉和生物，则是一家在研发领域具有较强实力的港交所主板上市公司，拥有多个具有潜力的药物管线。然而，近年来，面对资本寒冬和激烈的市场竞争，两家企业都面临各自的挑战。 此次合并，对于亿腾医药而言，无疑是...
Source Link近日，嘉和生物与亿腾医药联合宣布了一项具有深远影响的合并协议，标志着亿腾在上市的道路上迈出了重要一步。 亿腾医药经过多年的转型升级，已逐步发展成为一家具备研发、生产、供应链和销售综合能力的医药企业。而嘉和生物，则是一家在研发领域具有较强实力的港交所主板上市公司，拥有多个具有潜力的药物管线。然而，近年来，面对资本寒冬和激烈的市场竞争，两家企业都面临各自的挑战。 此次合并，对于亿腾医药而言，无疑是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.